# 1. Financial Performance ## A. Key Figures * EBITDA: ₹249.66 Mn Q2 FY26 (+1.9%) · ₹496.22 Mn H1 FY26 (+7.3%) * **PAT:** **₹88.28 Mn** Q2 FY26 (margin: 11.2%) · **₹1530.72 Mn** H1 FY26 * EPS: ₹3.53 H1 FY26 ## B. Revenue Growth * **Strong Volume-Driven Expansion:** Revenue growth fueled by higher patient volumes and network expansion, with half-year revenue surpassing ₹150,000 crore for the first time. ## C. EBITDA & PAT * **Margin Pressure Amid Growth:** EBITDA margin decline in Q2 attributed to adverse weather and seasonal festivities, despite solid top-line growth. * **Headwinds in Mature Centers:** Mature facilities saw EBITDA dip due to flooding and lower footfall, impacting overall profitability. * **Dilution from Expansion & Subsidiary:** Margin contraction below **34%** driven by new center costs, a ₹4 crore revenue impact, and underperformance in a subsidiary, with recovery expected. * **Pricing Pressure on Per-Patient Earnings:** EBITDA per patient declined despite rising test volumes, due to introductory discounts and increased **1% B2B mix** with discounted packages. ## D. EPS & Margins * **Earnings Growth Outpaces Profitability:** H1 EPS rose to ₹53 from ₹43, reflecting strong earnings leverage even as margins faced structural and temporary headwinds. --- # 2. Center Expansion & Network ## A. Key Figures * **Total Centers:** **63** as of September 2025 * **New Centers Opened (H1 FY26):** **3** (1 PPP, 1 large, 1 small) * **Expansion Pipeline:** **5 large** and **13 small** centers planned for FY26 * Revenue from New Centers (H1): ₹1.37 Cr * **EBITDA Loss from New Centers (H1):** **₹3 Cr** * **Annual Organic Capex:** **₹70 Cr** * **Mature Center EBITDA Margin:** **37–38%** * **New Center Breakeven:** **7 of 15** <1-year-old centers have reached breakeven ## B. Network Growth & Strategy * **Expansion Momentum:** Robust pipeline of **18 to 20 total center additions** in FY26, including Suraksha, PPP, and specialty centers, with **five large and seven small centers already opened**. * **Geographic Ambition:** Strategic push into **underserved regions like the Northeast** and inorganic growth via **acquisitions in fragmented markets** to accelerate footprint. * **Guidance Clarity:** FY26 target of **12–15 own-brand centers** excludes Fetomat, AIIR, and PPP models, resolving apparent discrepancy in expansion outlook. ## C. Center Maturity & Margin Trajectory * **Ramp-Up Dynamics:** **15 newly opened centers** are still scaling, with **7 already at breakeven**, signaling efficient ramp in core markets despite near-term EBITDA drag. * **Operating Leverage Ahead:** New centers to contribute **₹22 Cr in revenue** this year; long-term margin expansion expected as **33% of centers mature** and reach optimal utilization. * **Revenue Benchmarks:** Large centers generate **₹2–5 Cr** in first-year revenue, while small centers target **₹90 Lakh** annually when fully operational. ## D. Network Optimization & Partnerships * **Strategic Closures:** Two small centers closed—one due to **hospital self-sufficiency**, another to **avoid cannibalization** from a nearby large center—demonstrating disciplined portfolio management. * **PPP & Specialty Integration:** Limited PPP focus with **one MRI center in Kolkata**; **full Fetomat integration planned within 3–5 years** to boost accessibility and margin accretion. --- # 3. Volume & Pricing Trends ## A. Key Figures * **Tests Performed:** **4.13 Mn** H1 FY26 (+24% YoY) · **Patients Served:** **0.71 Mn** H1 FY26 (+17% YoY) * **Revenue per Patient:** **₹2,120** H1 FY26 (+1.0% YoY) · **EBITDA per Patient:** **₹695** H1 FY26 (-8.7% YoY) * **Revenue Mix:** **93% B2C** · **7% B2B** ## B. Test Volume Growth * **Strong Volume Momentum:** Test volumes and patient base expanded at a robust double-digit pace, reflecting increased market penetration and diagnostic demand. ## C. Revenue per Patient * **Pricing Resilience:** Revenue per patient showed slight improvement despite a shift in business mix and competitive dynamics. * **Margin Pressure:** EBITDA per patient declined meaningfully, indicating cost or mix headwinds despite operational scale gains. ## D. B2B vs B2C Mix * **Dominant B2C Model:** Business remains heavily skewed toward higher-margin B2C, which continues to drive revenue and profitability. * **Strategic B2B Ties:** B2B segment, though smaller, includes marquee partners like **Reliance** and provides access to institutional channels despite lower realization. --- # 4. Product & Segment Performance ## A. Key Figures * **Test Mix:** **48%** radiology · **52%** pathology (no YoY change) * **Genomics Revenue (H1):** **₹55 Lakh** (Fetomat division) ## B. Radiology & Pathology Mix * **Stable Core Mix:** Radiology and pathology contributions remain balanced with no material shift year-on-year, reflecting consistent demand and service alignment. * **Trust-Driven Growth:** Strong physician relationships and **in-house medical engagement** in local vernacular enhance credibility, driving referrals and prescription loyalty. * **Regional Advantage:** Proximity to Kolkata and cultural fluency reinforce competitive differentiation, strengthening doctor and patient confidence. ## C. Genomics Business * **Strategic Growth Vector:** Newly acquired Fetomat Genomics represents an early-stage but high-potential expansion into a **regionally unmet diagnostic need**, with Suraksha as the **only commercial genomic lab in Eastern India**. * **Scalable B2B Model:** Genomics growth to be fueled by hospital partnerships and **leveraged existing infrastructure**, with B2B revenue expected to rise over the next 2–3 years. * **Margin Outlook:** Margins currently not measurable due to pre-scale operations; no long-term margin dilution expected as business scales. ## D. Reference Lab Utilization * **High Operating Leverage:** Reference lab operates well below capacity with **5x headroom**, enabling significant volume absorption without incremental capex. --- # 5. Cost Structure & Efficiency ## A. Key Figures * **Rental Expenses:** ₹11 Cr H1 (+₹80 L QoQ) * Other Expenses: ~40% of revenue in Q2, up from 36–38% * Professional Fees Increase: ₹1.6 Cr (doctors) · ₹80 L (legal) * **COGS as % of Total Costs:** 12–13% ## B. Rental & Overhead Costs * **Cost Inflation Pressures:** Sharp rise in other expenses driven by **₹80 lakh** rental increase, **₹1 crore** administrative growth from expansion, and one-time **₹25 lakh** asset write-off. * **New Center Margin Resilience:** Despite high growth phase and low revenue bases, newer centers (<24 months) show **improving EBITDA margins**, supported by operating leverage and volume ramp. * **GST Impact:** Introduction of RCM under GST from November 2024 adds administrative and cash flow complexity, though not directly impacting P&L. ## C. Input Cost Savings * **Limited Benefit from Input Tax Reductions:** Pathology input GST cut (12% → 5%) yields modest COGS relief, but low COGS share (**12–13% of total costs**) makes overall impact **not material** to profitability. * **Timing of Savings:** Cost reductions from lower input taxes expected to reflect in **Q3 (Oct–Dec)** financials. ## D. Corporate Cost Absorption * **Economies of Scale Building:** Corporate overheads (HO, management, central lab) are fully allocated across centers; **per-center burden declines with network expansion**, supporting future margin expansion. --- # 6. Demand & Operational Risks ## A. Key Figures * Revenue Loss: INR3.5 Cr in Q2 due to flooding · INR3–4 Cr total shortfall cited ## B. Weather Disruptions * **Severe Operational Impact:** Torrential rains and flooding caused near-total shutdown for four days, reducing operations to **10% of normal levels** and significantly disrupting patient and doctor mobility. * **Material Financial Impact:** Unplanned weather event led to a meaningful revenue shortfall and pressured EBITDA margin due to zero footfall during peak disruption. * **Vulnerability to Regional Demand:** **25–30% of patients** originate from outside districts, making revenue stream susceptible to weather-related travel constraints. ## C. Festival Impact * **Minimal Surprise Effect:** Durga Puja festivities, occurring earlier in September 2025, were factored into planning and had only a minor, expected impact on revenue with no material EBITDA effect. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **15%** FY26 target · **15%–20%** multi-year outlook * **EBITDA Margin Guidance:** **33%–34%** FY26 target · **33%–35%** expected over next few quarters * **Centre Additions:** **12–15** planned for FY26, as confirmed ## B. Growth & Market Strategy * **Conservative but Confident Outlook:** Management maintains intentionally cautious revenue guidance despite **30% increase in store additions**, reflecting disciplined forecasting and regional variability. * **Expansion Momentum:** New centre ramp-up and **genomic lab launch** expected to drive H2 improvement and deepen regional market penetration. ## C. Margin & Cost Dynamics * **Margin Recovery Trajectory:** EBITDA margins on path to recover and expand, supported by scaling operations and **improved cost apportionment** post Q2 challenges. * **Favorable CapEx Impact:** Recent **GST reduction on medical equipment and inputs** (18% → 5%, 12% → 5%) to meaningfully lower capital expenditure costs. ## D. Funding & Strategic Initiatives * **Self-Funded Growth:** FY26 capex to be financed through **internal accruals**, underpinned by an underleveraged balance sheet with debt capacity available. * **Inorganic & Digital Expansion:** Company is actively evaluating **acquisition opportunities** and developing a **loyalty scheme software** to boost customer retention.